Stratagene CEO Says More Adverse Court Rulings Could Be 'Lethal' for Company | GenomeWeb
At an investors’ conference this week Stratagene shareholders peppered company officials with questions about the firm’s recent litigation woes, causing Chairman and CEO Joe Sorge to say that a continuation of adverse rulings against the firm could be “potentially lethal.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.